


Application No: 10/532765

This listing of claims will replace all prior versions and listings of claims in the application.

Listing of Claims:

1. (Currently Amended) A compound of formula I:



wherein

A is selected from O and S;

X is selected from

phenyl optionally substituted with up to 5 substituents each independently selected from halo, C₁-C₄ alkyl and C₁-C₄ alkoxy;

thienyl optionally substituted with up to 3 substituents each independently selected from halo and C₁-C₄ alkyl; and

C₂-C₈ alkyl, C₂-C₈ alkenyl, C₃-C₈ cycloalkyl and C₄-C₈ cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, -CF₃, -CN and -CONH₂;

Y is selected from dihydrobenzothienyl, benzothiazolyl, benzoisothiazolyl, ~~quinolyl, isequinolyl, naphthyridyl, quinolin-5-yl, isoquinolin-5-yl, naphthyridin-5-yl, and thienopyridyl-thienopyridinyl~~, each of which may be optionally substituted with up to 4 or, where possible, up to 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano;

Z is selected from H, OR₃ or F, wherein R₃ is selected from H, C₁-C₆ alkyl and phenyl C₁-C₆ alkyl;

Application No: 10/532765

R_1 and R_2 are each independently H or C_1 - C_4 alkyl;

or pharmaceutically acceptable salt thereof.


2. (Original) A compound as claimed in claim 1, wherein A is O.

3. (Original) A compound as claimed in claim 1, wherein A is S.


4. (Previously Presented) A compound as claimed in any one of claims 1-3, wherein one of R_1 and R_2 is H.

5. (Previously Presented) A compounds as claimed in any one of claims 1-3, wherein one of R_1 and R_2 is H and the other is methyl.

6. (Previously Presented) A compound as claimed in any one of claims 1-3, wherein the compound possesses the stereochemistry defined in formula



7. (Original) A compound as claimed in claim 6, wherein the compound possesses the stereochemistry defined in formula III



8. (Previously Presented) A compound as claimed in 5 wherein Z is H.

9. (Previously Presented) A compound as claimed in 5, wherein X is unsubstituted phenyl or phenyl which is mono-, di- or tri- substituted with substituents independently selected from halo, C_1 - C_4 alkyl and C_1 - C_4 alkoxy.

Application No: 10/532765

10. (Original) A compound as claimed in claim 9, wherein X is unsubstituted phenyl or phenyl which is mono-substituted with fluorine.
11. (Previously Presented) A compound as claimed in 5, wherein Y is dihydrobenzothienyl optionally substituted with up to 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano.
12. (Original) A compound as claimed in claim 11, wherein Y is unsubstituted dihydrobenzothienyl or dihydrobenzothienyl which is mono-substituted with fluorine.
13. (Previously Presented) A compound as claimed in 10, wherein Y is benzothiazolyl or benzoisothiazolyl, each of which may be optionally substituted with up to 4 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano.
14. (Original) A compound as claimed in claim 13, wherein Y is unsubstituted benzothiazolyl, unsubstituted benzoisothiazolyl, benzothiazolyl which is mono-substituted with CH₃ or benzoisothiazolyl which is mono-substituted with CH₃.
15. (Currently Amended) A compound as claimed in 10, wherein Y is ~~thienopyridyl~~ thienopyridinyl optionally substituted with up to 4 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano.
16. (Previously Presented) A compound as claimed in 5, wherein the point of attachment of the group Y to the O or S atom is attachment at the 7 position.
17. (Previously Presented) A compound as claimed in 5, wherein the point of attachment of the group Y to the O or S atom is attachment at the 4 position.
18. (Currently Amended) A compound as claimed in claim 5, wherein Y is ~~quinolyl, isoquinolyl or naphthyridyl~~ quinolin-5-yl, isoquinolin-5-yl or naphthyridin-5-yl, each of which may be optionally substituted with up to 5 substituents each independently selected from halo, C₁-C₄ alkyl, C₁-C₄ alkoxy, C₁-C₄ alkyl-S(O)_n- where n is 0, 1 or 2, nitro, acetyl, -CF₃, -SCF₃ and cyano.

Application No: 10/532765

19. (Original) A compound as claimed in claim 18, wherein the point of attachment of the group 10 Y to the O or S atom is attachment at the 4 position.
20. (Original) A compound as claimed in claim 18, wherein the point of attachment of the group Y to the O or S atom is attachment at the 5 position.
21. (Original) A compound as claimed in claim 18, wherein the point of attachment of the group Y to the O or S atom is attachment at the 6 position.
22. (Previously Presented) A pharmaceutical composition comprising a compound of formula I or a pharmaceutically acceptable salt thereof, as defined in claim 1, together with a pharmaceutically acceptable diluent or carrier.
23. (Previously Presented) A compound of formula I or a pharmaceutically acceptable salt thereof, as defined in claim 1, for use as a pharmaceutical.
24. (Previously Presented) A compound of formula I or a pharmaceutically acceptable salt thereof, as defined in claim 1, for use as a selective inhibitor of the reuptake of both serotonin and norepinephrine.
25. (Previously Presented) A compound of formula I or a pharmaceutically acceptable salt thereof, as defined in claim 1 for use in the treatment of a disorder associated with serotonin and norepinephrine dysfunction in mammals.
26. (Previously Presented) A compound of formula I or a pharmaceutically acceptable salt thereof, as defined in claim 1, for use in the treatment of a disorder selected from selected from depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation, hot flushes/flushes and pain.

Claims 27-32 (Cancelled)

33. (Previously Presented) A method for treating disorders associated with serotonin and norepinephrine dysfunction in mammals, comprising administering to a patient in need thereof an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof, as defined in claim 1

Application No: 10/532765

34. (Original) A method as claimed in claim 33, wherein the disorder is selected from depression, OCD, anxiety, memory loss, urinary incontinence, conduct disorders, ADHD, obesity, alcoholism, smoking cessation, hot flushes/flushes and pain.
35. (Original) A method as claimed in claim 33 or 34, wherein the disorder is pain.